Renaissance Technologies - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 171 filers reported holding BRIDGEBIO PHARMA INC in Q2 2022. The put-call ratio across all filers is 0.46 and the average weighting 0.3%.

Quarter-by-quarter ownership
Renaissance Technologies ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q3 2023$15,404
+21.6%
584,146
-23.5%
0.03%
+52.9%
Q1 2023$12,663
+61.4%
763,746
-25.8%
0.02%
+54.5%
Q4 2022$7,848
-99.9%
1,029,946
-24.6%
0.01%
-42.1%
Q3 2022$13,585,000
+262.1%
1,366,746
+230.7%
0.02%
+375.0%
Q2 2022$3,752,000
-48.6%
413,246
+248.6%
0.00%
-55.6%
Q1 2021$7,302,000118,5460.01%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q2 2022
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$160,016,45665.94%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$819,077,80528.79%
Cormorant Asset Management, LP 4,662,530$122,950,9167.17%
Frazier Life Sciences Management, L.P. 2,725,949$71,883,2754.77%
Octagon Capital Advisors LP 971,639$25,622,1203.94%
M28 Capital Management LP 121,200$3,196,0443.66%
VIKING GLOBAL INVESTORS LP 25,120,991$662,440,5332.69%
BOONE CAPITAL MANAGEMENT LLC 313,381$8,263,8572.61%
Fernwood Investment Management, LLC 235,620$6,213,2992.23%
SOUTHPORT MANAGEMENT, L.L.C. 15,000$395,5502.15%
View complete list of BRIDGEBIO PHARMA INC shareholders